Glimepiride PCD Pharma Franchise Company
Cafoli Lifecare offers an extensive Glimepiride PCD pharma franchise built on 26 formulations across tablets and metformin and pioglitazone combinations, all manufactured at WHO-GMP certified facilities. This depth gives franchise partners a core, high-volume antidiabetic line for diabetologists and physicians.
What is Glimepiride?
Glimepiride is a third-generation sulfonylurea antidiabetic. It lowers blood glucose primarily by stimulating insulin release from pancreatic beta cells, and is valued for once-daily dosing and a comparatively lower hypoglycaemia risk within its class. Read its profile on MedlinePlus.
Therapeutic Applications
Glimepiride is prescribed for type 2 diabetes mellitus to improve glycaemic control, most commonly in dual and triple fixed-dose combinations with metformin and/or pioglitazone. Its once-daily profile suits long-term maintenance therapy. Prescriptions come mainly from diabetologists, endocrinologists and general physicians.
Why Glimepiride is a High-Potential Molecule for Distributors
Glimepiride-based combinations are among the most prescribed oral antidiabetic products in India, sitting at the centre of dual and triple fixed-dose therapy for the vast type 2 diabetes population. With 26 formulations spanning every strength and combination, and lifelong continuous dosing, a distributor gains a foundational, fast-moving diabetes SKU family with dependable monthly repeat demand.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- MedlinePlus: Glimepiride
- PubChem: Glimepiride
Our formulations of Glimepiride find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: